Evidence map›Paper›PMID 39519433›Full record

Trial reportNutrients2024

Short-Term Effects of Escalating Doses of Cholecalciferol on FGF23 and 24,25(OH)

Jessica Pepe, Luciano Colangelo, Roberta Pilotto, Viviana De Martino, Carla Ferrara, Alfredo Scillitani, Mirella Cilli, Salvatore Minisola, Ravinder Singh, Cristiana Cipriani

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica PepeDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.
Luciano ColangeloDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-5835-9310
Roberta PilottoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.
Viviana De MartinoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-7034-7718
Carla FerraraIstituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-8628-829X
Alfredo ScillitaniUnit of Endocrinology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, 71013 Foggia, Italy.
Mirella CilliDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.
Salvatore MinisolaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0001-6525-0439
Ravinder SinghDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Cristiana CiprianiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-0141-1202

Funding

This study was partly funded by an unrestricted grant from Nycomed pharmaceutical company. This study was partly funded by an unrestricted grant from Nycomed pharmaceutical company.
6 · The paper itself

Abstract

backgroundThere are few and controversial results on 24,25(OH)

methodsTwenty-seven subjects with 25(OH)D < 30 ng/mL were randomized into three groups to receive a single oral dose of 25,000 I.U. or 600,000 I.U. of cholecalciferol or placebo, respectively. We measured 25(OH)D, 1,25(OH)

resultsThere was an increase in 25(OH)D and 1,25 (OH)

conclusions25(OH)D and 1,25(OH)D levels significantly increased following 600,000 IU cholecalciferol administration compared to 25,000 I.U. and placebo. Following the massive administration of cholecalciferol, the CYP24A1 enzyme is actively involved in catabolism, thus, avoiding toxic effects.

Indexed as

CholecalciferolFibroblast Growth Factor-23Fibroblast Growth FactorsVitamin DAdultDietary SupplementsDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedVitamin D DeficiencyYoung Adult24,25-dihydroxyvitamin D25-hydroxyvitamin DCholecalciferolFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsVitamin D24,25(OH)2DcholecalciferolFGF23vitamin D

Identifiers

PMID39519433
PMCPMC11547203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.